Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 1
2007 6
2008 1
2009 2
2010 5
2011 11
2012 6
2013 7
2014 7
2015 7
2016 11
2017 9
2018 11
2019 13
2020 9
2021 16
2022 9
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma.
Ishihara H, Nemoto Y, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: kobayashi h. Clin Genitourin Cancer. 2024 Apr;22(2):549-557.e5. doi: 10.1016/j.clgc.2024.01.010. Epub 2024 Jan 15. Clin Genitourin Cancer. 2024. PMID: 38281878
Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells.
Koya T, Yoshida K, Togi M, Niida Y, Togi S, Ura H, Mizuta S, Kato T Jr, Yamada S, Shibata T, Liu YC, Yuan SS, Wu DC, Kobayashi H, Utsugisawa T, Kanno H, Shimodaira S. Koya T, et al. Among authors: kobayashi h. Cancers (Basel). 2023 Jul 14;15(14):3627. doi: 10.3390/cancers15143627. Cancers (Basel). 2023. PMID: 37509288 Free PMC article.
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: kobayashi h. Target Oncol. 2023 Mar;18(2):209-220. doi: 10.1007/s11523-023-00956-8. Epub 2023 Mar 21. Target Oncol. 2023. PMID: 36941516
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: kobayashi h. Target Oncol. 2023 Jan;18(1):159-168. doi: 10.1007/s11523-022-00940-8. Epub 2022 Dec 26. Target Oncol. 2023. PMID: 36571708
121 results